Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Oct;70(4):762–766. doi: 10.1038/bjc.1994.392

Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma.

C S McArdle 1, D J Kerr 1, P O'Gorman 1, H A Wotherspoon 1, H Warren 1, D Watson 1, B J Vinké 1, J W Dobbie 1, D I el Eini 1
PMCID: PMC2033424  PMID: 7917936

Abstract

Five patients with advanced colorectal and gastric carcinoma with peritoneal deposits were treated by continuous weekdays intraperitoneal (i.p.) instillation of 5-fluorouracil (5-FU) 200 mg m-2 day-1 in a novel dialysate solution that ensures maximal exposure of peritoneal areas liable to bear tumours for 24 h. A solution of icodextrin, a glucose polymer, in a 21 twin-bag delivery system allowed a single daily exchange and demonstrated the feasibility of long-term continuous ambulatory treatment with up to 17.4 g of 5-FU, delivered intraperitoneally, in this initial study. During the entire study, there were 235 fluid exchanges or 470 connections and disconnections and no bacterial peritonitis or exit site infection were observed. There was no treatment-associated toxicity worse than WHO grade 2. Drug concentrations in both peritoneal and plasma compartments followed a first-order model with similar half-life value of 1.3 h. 5-FU pharmacokinetic parameters (half-life values, total body clearance, peritoneal clearance and pharmacological advantage of the i.p. route) with this novel icodextrin carrier solution were similar to those obtained in other referenced pharmacokinetic studies with other carrier solutions (dextrose dialysate and lactated Ringer's solutions). This confirms that icodextrin solution is physiologically neutral, drug compatible and allows adequate dwell times with constant fluid balance for long-term continuous intraperitoneal chemotherapy. The pharmacokinetic parameters from this study will be used to design a loading dose infusion schedule in an attempt to maintain steady-state i.p. 5-FU levels in a new multicentre phase I trial.

Full text

PDF
762

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonsen S., Pedersen F. B., Wang P. Leukocytes in peritoneal dialysis effluents. Danish Study Group on Peritonitis in Dialysis (DASPID). Perit Dial Int. 1991;11(1):43–47. [PubMed] [Google Scholar]
  2. Arbuck S. G., Trave F., Douglass H. O., Jr, Nava H., Zakrzewski S., Rustum Y. M. Phase I and pharmacologic studies of intraperitoneal leucovorin and 5-fluorouracil in patients with advanced cancer. J Clin Oncol. 1986 Oct;4(10):1510–1517. doi: 10.1200/JCO.1986.4.10.1510. [DOI] [PubMed] [Google Scholar]
  3. Bates C. D., Watson D. G., Willmott N., Logan H., Goldberg J. The analysis of 5-fluorouracil in human plasma by gas chromatography-negative ion chemical ionization mass spectrometry (GC-NICIMS) with stable isotope dilution. J Pharm Biomed Anal. 1991;9(1):19–21. doi: 10.1016/0731-7085(91)80231-w. [DOI] [PubMed] [Google Scholar]
  4. CLARKSON B., O'CONNOR A., WINSTON L., HUTCHISON D. THE PHYSIOLOGIC DISPOSITION OF 5-FLUOROURACIL AND 5-FLUORO-2'-DEOXYURIDINE IN MAN. Clin Pharmacol Ther. 1964 Sep-Oct;5:581–610. doi: 10.1002/cpt196455581. [DOI] [PubMed] [Google Scholar]
  5. Campora E., Esposito M., Civalleri D., Gogioso L., Decian F., Balletto N., Falcone A., Nobile M. T., Parodi B., Cafaggi S. Serum, urine and peritoneal fluid levels of 5-FU following intraperitoneal administration. Anticancer Res. 1987 Jul-Aug;7(4B):829–832. [PubMed] [Google Scholar]
  6. Casper E. S., Kelsen D. P., Alcock N. W., Lewis J. L., Jr Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep. 1983 Mar;67(3):235–238. [PubMed] [Google Scholar]
  7. Christophidis N., Mihaly G., Vajda F., Louis W. Comparison of liquid- and gas-liquid chromatographic assays of 5-fluorouracil in plasma. Clin Chem. 1979 Jan;25(1):83–86. [PubMed] [Google Scholar]
  8. Demicheli R., Jirillo A., Bonciarelli G., Bellini A., Petrosino L., Bigi L., Garusi G. F. Pharmacological data and technical feasibility of intraperitoneal 5-fluorouracil administration. Tumori. 1982 Oct 31;68(5):437–441. doi: 10.1177/030089168206800514. [DOI] [PubMed] [Google Scholar]
  9. Ekberg H., Tranberg K. G., Persson B., Jeppsson B., Nilsson L. G., Gustafson T., Andersson K. E., Bengmark S. Intraperitoneal infusion of 5-FU in liver metastases from colorectal cancer. J Surg Oncol. 1988 Feb;37(2):94–99. doi: 10.1002/jso.2930370206. [DOI] [PubMed] [Google Scholar]
  10. Fok F. K., Bewtra C., Hammeke M. D. Cytology of peritoneal fluid from patients on continuous ambulatory peritoneal dialysis. Acta Cytol. 1989 Sep-Oct;33(5):595–598. [PubMed] [Google Scholar]
  11. Goldberg J. A., Kerr D. J., Willmott N., McKillop J. H., McArdle C. S. Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. Br J Cancer. 1988 Feb;57(2):186–189. doi: 10.1038/bjc.1988.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hallenbeck P., Sanniez C. K., Ryan A. B., Neiley B., Sugarbaker P. H. Cytoreductive surgery and intraperitoneal chemotherapy. Treatment for peritoneal carcinomatosis. AORN J. 1992 Jul;56(1):50–72. doi: 10.1016/s0001-2092(07)66649-6. [DOI] [PubMed] [Google Scholar]
  13. Leichman C. G., Leichman L., Spears C. P., Rosen P. J., Jeffers S., Groshen S. Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. J Natl Cancer Inst. 1993 Jan 6;85(1):41–44. doi: 10.1093/jnci/85.1.41. [DOI] [PubMed] [Google Scholar]
  14. Lokich J. J., Ahlgren J. D., Gullo J. J., Philips J. A., Fryer J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989 Apr;7(4):425–432. doi: 10.1200/JCO.1989.7.4.425. [DOI] [PubMed] [Google Scholar]
  15. Mistry C. D., Mallick N. P., Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet. 1987 Jul 25;2(8552):178–182. doi: 10.1016/s0140-6736(87)90764-1. [DOI] [PubMed] [Google Scholar]
  16. Piccart M. J., Speyer J. L., Markman M., ten Bokkel Huinink W. W., Alberts D., Jenkins J., Muggia F. Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol. 1985 Sep;12(3 Suppl 4):90–96. [PubMed] [Google Scholar]
  17. SUHRLAND L. G., WEISBERGER A. S. INTRACAVITARY 5-FLUOROURACIL IN MALIGNANT EFFUSIONS. Arch Intern Med. 1965 Sep;116:431–433. doi: 10.1001/archinte.1965.03870030111019. [DOI] [PubMed] [Google Scholar]
  18. Schilsky R. L., Choi K. E., Grayhack J., Grimmer D., Guarnieri C., Fullem L. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol. 1990 Dec;8(12):2054–2061. doi: 10.1200/JCO.1990.8.12.2054. [DOI] [PubMed] [Google Scholar]
  19. Seifert P., Baker L. H., Reed M. L., Vaitkevicius V. K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975 Jul;36(1):123–128. doi: 10.1002/1097-0142(197507)36:1<123::aid-cncr2820360108>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  20. Speyer J. L., Collins J. M., Dedrick R. L., Brennan M. F., Buckpitt A. R., Londer H., DeVita V. T., Jr, Myers C. E. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res. 1980 Mar;40(3):567–572. [PubMed] [Google Scholar]
  21. Speyer J. L., Sugarbaker P. H., Collins J. M., Dedrick R. L., Klecker R. W., Jr, Myers C. E. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res. 1981 May;41(5):1916–1922. [PubMed] [Google Scholar]
  22. Speyer J. L. The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol. 1985 Sep;12(3 Suppl 4):23–28. [PubMed] [Google Scholar]
  23. Sugarbaker P. H., Gianola F. J., Speyer J. C., Wesley R., Barofsky I., Meyers C. E. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery. 1985 Sep;98(3):414–422. [PubMed] [Google Scholar]
  24. Sugarbaker P. H., Graves T., DeBruijn E. A., Cunliffe W. J., Mullins R. E., Hull W. E., Oliff L., Schlag P. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res. 1990 Sep 15;50(18):5790–5794. [PubMed] [Google Scholar]
  25. Sugarbaker P. H. Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy. J Surg Oncol Suppl. 1991;2:36–41. doi: 10.1002/jso.2930480510. [DOI] [PubMed] [Google Scholar]
  26. WEISBERGER A. S., LEVINE B., STORAASLI J. P. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc. 1955 Dec 31;159(18):1704–1707. doi: 10.1001/jama.1955.02960350004002. [DOI] [PubMed] [Google Scholar]
  27. Wahl R. L., Gyves J., Gross B. H., Cochran M., Juni J. E., Arnstein N. B., Lahti D., Ackermann R. J. SPECT of the peritoneal cavity: method for delineating intraperitoneal fluid distribution. AJR Am J Roentgenol. 1989 Jun;152(6):1205–1210. doi: 10.2214/ajr.152.6.1205. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES